Although, as described above, different KRAS mutations show a preference for activating different downstream signaling, hyperactivation of the mitogen-activated protein kinase (MAPK) pathway is generally recognized as a key feature in KRAS-driven lung cancer cells. Here, KRAS is linked to lung cancer.